Thermo Fisher to sell anatomic pathology business
Feb. 4, 2019—Thermo Fisher Scientific announced it has signed a definitive agreement to sell
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Thermo Fisher Scientific
Thermo Fisher inks deal to expand Oncomine Dx
June 2018—Thermo Fisher Scientific has signed agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of Oncomine Dx Target Test in support of clinical trials and drug development programs at the Japanese companies.
CMS extends coverage of Oncomine Dx test, 5/18
May 2018—Thermo Fisher Scientific announced its Oncomine Dx Target Test has been approved for coverage by the Centers for Medicare and Medicaid Services as part of the agency’s national coverage determination for next-generation sequencing in vitro diagnostic tests.
Thermo Fisher acquires IntegenX, 5/18
May 2018—Thermo Fisher Scientific has acquired IntegenX, a forensic DNA testing firm. IntegenX products include the RapidHIT platforms, software analysis tools, and related consumables that are compatible with Thermo Fisher’s short tandem repeat chemistries for human identification.
Thermo Fisher expands Oncomine portfolio, 4/18
April 2018—Thermo Fisher Scientific has expanded its Oncomine portfolio with two assays for liquid biopsy and immuno-oncology for clinical research. The company also announced its next-generation Ion AmpliSeq HD technology. The Ion Torrent Oncomine Pan-Cancer Cell-Free Assay enables reproducible detection and analysis of tumor DNA and RNA across all major classes of somatic mutations (SNVs, indels, CNVs, and fusions) from a single vial of blood, with as little as 1 ng of nucleic acid input, within two days.
Thermo Fisher unveils line of NGS instruments, 3/18
March 2018—Thermo Fisher Scientific announced the Ion GeneStudio S5 Series, a line of benchtop next-generation sequencing instruments that provides flexibility and scalability enabled by five Ion S5 chips, including the new Ion 550 chip, on a single platform. Research applications include cancer, inherited disease, and microbial and infectious diseases.
DNA purification reagents, 2/18
February 2018—Thermo Fisher Scientific released its MagMax DNA Multi-Sample Ultra 2.0 reagents, which provide genetic testing companies, labs, and service providers with high-throughput DNA extraction from blood, saliva, buffy coat, and buccal swabs. The next-generation reagents can purify DNA from 96 samples in 45 minutes on Thermo Scientific KingFisher instruments using a simplified protocol for either small- or large-volume sample input.
LabCorp, Cancer Genetics join Thermo Fisher program, 12/17
December 2017—LabCorp and Cancer Genetics have signed agreements with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. Each laboratory will participate in oncology-focused clinical trials in collaboration with pharmaceutical companies and Thermo Fisher.
Cell washer, 11/17
November 2017—The CW3 Cell Washer, from Thermo Scientific, is an FDA-cleared, fully automated, high-performance cell washer designed to enable precise, thorough, reproducible, and rapid blood cell washing of up to 24 tubes in a three-minute run.
Thermo Scientific leakproof vials, 10/17
October 2017—Thermo Scientific Samco Clicktainer leakproof vials have been developed to provide sample protection and user safety by enabling correct cap application. The vials are designed for the secure collection and handling of fluid, solid, and powder samples, including urine, sputum, and stool specimens; the lid-lock design makes them ideal for the secure transport of clinical, research, and forensic samples.